UPDATE: Allergan (AGN) Increases Quarterly Dividend 2.86% to $0.72; 1.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Allergen (AGN) PT Raised to $215 at BofA/Merrill Lynch
February 7, 2018 9:11 AM ESTBofA/Merrill Lynch raised its price target on Allergen (NYSE: AGN) to $215.00 (from $208.00) while maintaining a Buy rating.
... MoreAllergen (AGN) PT Raised to $215 at Credit Suisse; 'Positive CGRP Data Should Relieve Pain AGN Investors Have Been Feeling'
February 7, 2018 8:12 AM ESTCredit Suisse raised its price target on Allergen (NYSE: AGN) to $215.00 (from $214.00) while maintaining a Outperform rating.
... MoreAllergan (AGN): Good Results, PT To $215 - Deutsche Bank
February 7, 2018 8:11 AM ESTDeutsche Bank analyst, Gregg Gilbert, reiterated his Buy rating on shares of Allergen (NYSE: AGN) and raised the price target to $215 from $212 after the company reported solid 4Q results with revenue and EPS above and consensus driven by strong growth for the aesthetics business. The... More
Allergen (AGN) PT Raised to $242 at Leerink Partners
February 7, 2018 7:39 AM ESTLeerink Partners raised its price target on Allergen (NYSE: AGN) to $242.00 (from $237.00) while maintaining a Outperform rating.
Analyst Seamus Fernandez commented, "Following Tuesdays call we are incrementally more confident in the approvability of ubrogepant for acute migraine and AGNs ability to execute on 2018... More
Allergen (AGN) PT Lowered to $171 at Piper Jaffray
February 7, 2018 6:41 AM ESTPiper Jaffray lowered its price target on Allergen (NYSE: AGN) to $171.00 (from $176.00) while maintaining a Neutral rating.
... MoreAllergen (AGN) PT Lowered to $220 at Citi
February 7, 2018 6:20 AM ESTCiti lowered its price target on Allergen (NYSE: AGN) to $220.00 (from $240.00) while maintaining a Buy rating.
... MoreAllergen (AGN) PT Lowered to $212 at Deutsche Bank
February 7, 2018 6:00 AM ESTDeutsche Bank lowered its price target on Allergen (NYSE: AGN) to $212.00 (from $215.00) while maintaining a Buy rating.
... More